Jonathan Aschoff
Stock Analyst at Roth Capital
(0.49)
# 4,184
Out of 5,109 analysts
39
Total ratings
24.49%
Success rate
-35.04%
Average return
Main Sectors:
Stocks Rated by Jonathan Aschoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTHS Pelthos Therapeutics | Initiates: Buy | $57 | $26.50 | +115.09% | 1 | Nov 25, 2025 | |
| GTBP GT Biopharma | Initiates: Buy | $11 | $0.85 | +1,201.78% | 1 | Dec 2, 2024 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $19 → $21 | $8.64 | +143.06% | 2 | Sep 24, 2024 | |
| APVO Aptevo Therapeutics | Maintains: Buy | $11,100 → $5,920 | $0.93 | +636,390.70% | 3 | Sep 23, 2024 | |
| BRTX BioRestorative Therapies | Maintains: Buy | $15 → $18 | $1.18 | +1,425.42% | 4 | Aug 14, 2024 | |
| NUWE Nuwellis | Reiterates: Buy | $714 | $2.06 | +34,560.19% | 2 | Aug 13, 2024 | |
| GOVX GeoVax Labs | Initiates: Buy | $20 | $0.18 | +10,907.15% | 1 | Jul 16, 2024 | |
| MBRX Moleculin Biotech | Maintains: Buy | $1,000 | $3.90 | +25,541.03% | 2 | Apr 12, 2024 | |
| CLRB Cellectar Biosciences | Maintains: Buy | $600 → $840 | $2.76 | +30,334.78% | 4 | Mar 28, 2024 | |
| MNMD Mind Medicine (MindMed) | Maintains: Buy | $25 → $36 | $13.43 | +168.06% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3,750 → $18,000 | $2.83 | +635,942.40% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $12.55 | +139.04% | 3 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $200 | $6.36 | +3,044.65% | 1 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $14 | $5.75 | +143.48% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7,200 → $21,600 | $0.87 | +2,482,373.28% | 2 | Feb 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $8 | $1.44 | +455.56% | 1 | Jun 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $2.20 | +4,445.45% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.72 | +55,455.56% | 1 | Nov 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $9.19 | +313.49% | 1 | Mar 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $96 | $2.25 | +4,166.67% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $1.77 | +634.46% | 1 | Dec 19, 2019 |
Pelthos Therapeutics
Nov 25, 2025
Initiates: Buy
Price Target: $57
Current: $26.50
Upside: +115.09%
GT Biopharma
Dec 2, 2024
Initiates: Buy
Price Target: $11
Current: $0.85
Upside: +1,201.78%
Zevra Therapeutics
Sep 24, 2024
Maintains: Buy
Price Target: $19 → $21
Current: $8.64
Upside: +143.06%
Aptevo Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $11,100 → $5,920
Current: $0.93
Upside: +636,390.70%
BioRestorative Therapies
Aug 14, 2024
Maintains: Buy
Price Target: $15 → $18
Current: $1.18
Upside: +1,425.42%
Nuwellis
Aug 13, 2024
Reiterates: Buy
Price Target: $714
Current: $2.06
Upside: +34,560.19%
GeoVax Labs
Jul 16, 2024
Initiates: Buy
Price Target: $20
Current: $0.18
Upside: +10,907.15%
Moleculin Biotech
Apr 12, 2024
Maintains: Buy
Price Target: $1,000
Current: $3.90
Upside: +25,541.03%
Cellectar Biosciences
Mar 28, 2024
Maintains: Buy
Price Target: $600 → $840
Current: $2.76
Upside: +30,334.78%
Mind Medicine (MindMed)
Mar 7, 2024
Maintains: Buy
Price Target: $25 → $36
Current: $13.43
Upside: +168.06%
Mar 5, 2024
Maintains: Buy
Price Target: $3,750 → $18,000
Current: $2.83
Upside: +635,942.40%
Feb 20, 2024
Reiterates: Buy
Price Target: $30
Current: $12.55
Upside: +139.04%
Aug 29, 2023
Reiterates: Buy
Price Target: $200
Current: $6.36
Upside: +3,044.65%
Aug 14, 2023
Reiterates: Buy
Price Target: $14
Current: $5.75
Upside: +143.48%
Feb 14, 2023
Maintains: Buy
Price Target: $7,200 → $21,600
Current: $0.87
Upside: +2,482,373.28%
Jun 15, 2022
Reinstates: Buy
Price Target: $8
Current: $1.44
Upside: +455.56%
Feb 25, 2022
Initiates: Buy
Price Target: $100
Current: $2.20
Upside: +4,445.45%
Nov 24, 2021
Initiates: Buy
Price Target: $400
Current: $0.72
Upside: +55,455.56%
Mar 11, 2021
Initiates: Buy
Price Target: $38
Current: $9.19
Upside: +313.49%
Nov 17, 2020
Downgrades: Sell
Price Target: $96
Current: $2.25
Upside: +4,166.67%
Dec 19, 2019
Initiates: Buy
Price Target: $13
Current: $1.77
Upside: +634.46%